5-HT |
5-hydroxytryptamine (serotonin) |
ADRs |
adverse drug reactions |
AMPA |
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (glutamate receptors) |
BDNF |
brain derived neurotrophic factor |
CNS |
central nervous system |
COX-2 |
cyclooxygenase 2 |
GABA |
gamma aminobutyric acid |
HPA |
hypothalamic-pituitary-axis |
SSRIs |
selective serotonin reuptake inhibitors |
Il |
interleukin |
INF-γ |
interferon-γ |
iNOS |
inducible nitric oxide synthase |
MAH |
marketing authorization holder |
MAOIs |
monoamine oxidase inhibitors |
MDD |
major depressive disorder |
NDRIs |
noradrenaline and dopamine reuptake inhibitors |
NE |
noradrenaline (norepinephrine) |
NF-κB |
nuclear factor-kappa factor |
NMDA |
N-methyl-D-aspartate (glutamate receptors) |
NRIs |
noradrenaline reuptake inhibitors |
OTC |
over the counter (drugs) |
OS |
oxidative stress |
SNRIs |
selective noradrenaline reuptake inhibitors |
SJW |
St. John’s wort |
TCAs |
tricyclic antidepressants |
TNF-α |
tumour necrosis alpha |
WHO |
World Health Organization |